US-based Sonde Health has signed a multi-year agreement with Koye Pharmaceuticals, a Mumbai-based specialty pharma organization focused on the Indian Pharmaceutical market, to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease (COPD) in India. This deal represents Sonde’s first partnership with a pharmaceutical company.

As part of this arrangement, Koye will leverage Sonde’s vocal biomarker development (VBD) platform, expanding upon its already existing respiratory responsive vocal biomarker, to create an entirely novel vocal biomarker for COPD in India. This will allow Koye to develop solutions that help track and treat respiratory health in COPD patients using their voice.

Sonde Health has previously developed and commercialized vocal biomarker technology to detect and monitor respiratory impairment. In early 2022, the company partnered with GN Group, a leading global manufacturer of hearing instruments and audiological diagnostics equipment and headsets, to create vocal biomarker technology to detect Mild Cognitive Impairment.

Preetish Toraskar, Founder and Director at Koye Pharmaceuticals said, “Not only is Sonde at the forefront of vocal biomarker technology, but their extensive experience in respiratory health will prove invaluable as we work to get this debilitating condition under control in India.”